Dr. Bharath Takulapalli is Founder CEO of iNanoBio, a startup developing advanced technologies at the interface of nanotechnology, biology and machine learning (ML). Bharath believes that, as a scientific community, we can preempt 90% of all diseases. Disease preemption implies detection in predisease stages, followed by early intervention and cure, before disease onset. To contribute, iNanoBio is developing two product platforms to extract 100x more information from systems biology (genotype and phenotype) than currently possible. First is a novel semiconductor nanopore transistor device to sequence the DNA 1000X faster than state of art, and 90% less expensive. The second is a firstofkind proteomic technology termed SPOC (Sensorintegrated Proteome on Chip) to study protein kinetic interactions at scale. We successfully developed functional prototypes of proteinbiosensor chips and SPOC Proteomics Inc is set for researchuse commercial launch in 2024 and CLIA tests in 202526. iNanoBio is based out of Menlo Park, California and Scottsdale, Arizona.
Novel SPOC Proteomic biosensor Technology to Study Proteins at Scale
Clinical & Research Tools Showcase:
iNanoBio is developing advanced technologies at the interface of nanotechnology, biology and machine learning (ML). iNanoBio's two novel product platforms aim to extract 100x information from systems biology than possible today (i) FENT for 1000x faster DNA sequencing (ii) SPOC for studying proteins at scale.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2023 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.